Laripront (Larypront)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceDequilinyl chloride + Lysozyme hydrochlorideDequilinyl chloride + Lysozyme hydrochloride
Similar drugsTo uncover
  • Laripront
    pills n / az. 
    Hexalo Trieding Limited     Cyprus
    • Dosage form: & nbsplozenges
    Composition:

    Active Ingredients:

    1 tablet contains:

    Dequalinium chloride 0.25 mg1)

    Lysozyme hydrochloride 10.00 mg2)

    Excipients:

    Povidone (polyvidone K 25, polyvinylpyrrolidone) 20.00 mg

    Magnesium stearate 15.00 mg

    Anisic aromatic essence 89617 0.50 mg

    Peppermint aromatic essence 89664 3.00 mg

    Sucrose 701.25 mg

    1)based on activity in 100%

    2)based on 100% activity, including 10% excess

    Description:White round tablets with a stamped lotus flower on both sides.
    Pharmacotherapeutic group:Anti-inflammatory agent for topical application
    ATX: & nbsp

    R.02.A.A   Antiseptics

    Pharmacodynamics:

    Lysozyme - a natural enzyme (mucopolysaccharidase), forming a complex with viruses and preventing their penetration into cells, has an antiviral effect. Has antimicrobial effect against gram-positive and some gram-negative bacteria due to destruction of the cell wall of microorganisms. In addition, lysozyme has anti-inflammatory, hemostatic and mucolytic effects due to blockade of histamine, inactivation of heparin and cleavage of mucopolysaccharides.

    Dequiline chloride is an antiseptic, effective against gram-positive and gram-negative microorganisms, as well as fungi. Possessing the ability to reduce the surface tension, ensures the penetration of active substances into deeper regions of the mucous membrane.

    Indications:

    - Infectious and inflammatory diseases of the mucous membrane of the oral cavity, pharynx and larynx: gingivitis, periodontitis, stomatitis (including candidiasis, thrush), pharyngitis, laryngitis, tonsillitis;

    - prevention of ARVI;

    - Sore throat and hoarseness of voice;

    - before and after surgical interventions in the oral cavity and pharynx (dental operations, jaw operations, maxillary sinuses, tonsils).

    Contraindications:Hypersensitivity to the components of the drug.
    Pregnancy and lactation:During pregnancy and lactation, it is possible to use the drug according to the indications.
    Dosing and Administration:

    For oral administration (keep in mouth, without chewing and not swallowing, until complete dissolution).

    1 tablet every 2-3 hours. After resorption of the tablet should refrain from eating food or liquids for 30 minutes.

    Side effects:In some cases, allergic reactions are possible.
    Overdose:Due to low systemic absorption of the drug, an overdose is unlikely.
    Interaction:There is no clinically relevant interaction with other drugs.
    Effect on the ability to drive transp. cf. and fur:Does not affect the ability to drive vehicles and control mechanisms.
    Form release / dosage:Lozenges.
    Packaging:10 tablets for resorption in a blister, 2 blisters together with instructions for use in a cardboard bundle.
    Storage conditions:Store at a temperature not higher than 25 ° C, in places inaccessible to children!
    Shelf life:

    3 years.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:P N008293 / 01
    Date of registration:06.12.2012 / 11.09.2012
    Expiration Date:Unlimited
    The owner of the registration certificate:Hexalo Trieding LimitedHexalo Trieding Limited Cyprus
    Manufacturer: & nbsp
    Representation: & nbspMask Rus, Open CompanyMask Rus, Open Company
    Information update date: & nbsp12.03.2018
    Illustrated instructions
      Instructions
      Up